Effect of individual plasma lipoprotein(a) variations in vivo on its competition with plasminogen for fibrin and cell binding: An in vitro study using plasma from children with idiopathic nephrotic syndrome

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 2, 2000, Pages 575-584

  Soulat, Thierry ^a   Loyau, Stéphane ^a   Baudouin, Véronique ^b   Maisonneuve, Lydia ^b   Hurtaud Roux, Marie France ^b   Schlegel, Nicole ^b   Loirat, Chantal ^b   Anglés Cano, Eduardo ^a,c  

^a BICÊTRE HOSPITAL   (France)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c Dept Environ Med Natl Inst Publ HIth   (Norway)

Author keywords

Apolipoprotein(a) isoforms; Binding, competitive; Lipoprotein(a); Lysine binding site; Plasminogen inhibition

Indexed keywords

ALBUMIN; ALPHA 2 ANTIPLASMIN; ANTIVITAMIN K; APOLIPOPROTEIN A; CELL MEMBRANE PROTEIN; CHOLESTEROL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FIBRIN; FIBRINOGEN; GLYCOPROTEIN; HEPARIN; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN A; M PROTEIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDNISONE; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ADOLESCENT; ARTICLE; ATHEROSCLEROSIS; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IDIOPATHIC DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NEPHROTIC SYNDROME; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN BINDING; THROMBOSIS;

EID: 0033964313     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.2.575     Document Type: Article

References (64)

1. Hoyer PF, Gonda S, Barthels M, Krohn HP, Brodehl J. Thromboembolic complications in children with nephrotic syndrome. Acta Paediatr Scand. 1986;75:804-810.
2. Mehls O, Andrassy K, Koderish J, Herzog U, Ritz E. Hemostasis and thromboembolism in children with nephrotic syndrome. J Pediatr. 1987;110:862-867.
3. Llach F. Thromboembolic complications in nephrotic syndrome. Postgrad Med. 1984;76:111-123.
4. Kanfer A. Coagulation factors in nephrotic syndrome. Am J Nephrol. 1990;10(suppl 1):63-68.
5. Gandrille S, Jouvin MH, Toulon P, Remy P, Fiessinger JN, Roncato M, Moatti N, Aiach M. A study of fibrinogen and fibrinolysis in 10 adults with nephrotic syndrome. Thromb Haemost. 1988;59:445-450.
6. Scheinman JI, Stiehm ER. Fibrinolysis studies in the nephrotic syndrome. Pediatr Res. 1971;5:206-212.
7. Loirat C, Pillion G, Schlegel N, Douenias R, Mathieu H. Etude des protéines de le coagulation et de la fibrinolyse au cours des syndromes néphrotiques chez l'enfant. Arch Fr Pediatr. 1979;36:56-63.
8. Lau SO, Thachuck JY, Hasegawa DK, Edson JR. Plasminogen and antithrombin III deficiencies in the childhood nephrotic syndrome associated with plasminogenuria and antithrombinuria. J Pediatr. 1980;96:390-392.
9. Faucher C, Doucet C, Baumelou A, Chapman J, Jacobs C, Thillet J. Elevated lipoprotein(a) levels in primary nephrotic syndrome. Am J Kidney Dis. 1993;22:808-813.
10. Vaziri ND, Gonzales EC, Shayestehfar B, Barton CH. Plasma levels and urinary excretion of fibrinolytic and protease inhibitory proteins in nephrotic syndrome. J Lab Clin Med. 1994;124:118-124.
11. Wanner C, Rader D, Bartens W, Krämer J, Brewer HB, Schollmeyer P, Wieland H. Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. Ann Intern Med. 1993;119:263-269.
12. Stenvinkel P, Berglund L, Heimbürger O, Pettersson E, Alvestrand A. Lipoprotein(a) in nephrotic syndrome. Kidney Int. 1993;44: 1116-1123.
13. Hong SY, Yang DH. Lipoprotein(a) levels and fibrinolytic activity in patients with nephrotic syndrome. Nephron. 1995;69:125-130.
14. Querfeld U, Lang M, Friedrich JB, Kohl B, Fiehn W, Schärer K. Lipoprotein(a) serum levels and apolipoprotein(a) phenotypes in children with chronic renal disease. Pediatr Res. 1993;34:772-776.
15. Garnotel R, Roussel B, Pennaforte F, Randoux A, Gillery P. Changes in serum lipoprotein(a) levels in children with corticosensitive nephrotic syndrome. Pediatr Nephrol. 1996;10:699-701.
16. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation. 1986;74:758-765.
17. Rhoads GG, Dahlen G, Berg K, Morton NE, Dannenberg AL. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA. 1986; 256:2540-2544.
18. Kronenberg F, Utermann G, Dieplinger H. Lipoprotein(a) in renal disease. Am J Kidney Dis. 1996;27:1-25.
19. Takegoshi T, Kitoh C, Haba T, Hirai JI, Wakasugi T, Saga T, Yamazaki Y, Mabuchi H. A study of the clinical significance of lipoprotein(a) in nephrotic syndrome. Jpn J Med. 1991;30:21-25.
20. Fujita T, Saito E, Ohi H, Yasugi T, Hatano M. Lipoprotein(a) predicts the risk of thrombogenic complications in nephrotic syndrome. Nephron. 1992;61:122.
21. Eaton DL, Fless GM, Kohr WJ, McLean JW, Xu QT, Miller CG, Lawn RM, Scanu AM. Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen. Biochemistry. 1987;84:3224-3228.
22. Petersen TE, Martzen MR, Ichinose A, Davie EW. Characterization of the gene for human plasminogen, a key proenzyme in the fibrinolytic system. J Biol Chem. 1990;265:6104-6111.
23. Summaria L, Hsieh B, Robbins KC. The specific mechanism of activation of human plasminogen to plasmin. J Biol Chem. 1967;242: 4279-4267.
24. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987;300:132-137.
25. Marcovina SM, Zhang ZH, Gaur VP, Albers JJ. Identification of 34 apolipoprotein(a) isoforms: differential expression of apolipoprotein(a) alleles between American blacks and whites. Biochem Biophys Res Commun. 1993;191:1192-1196.
26. Lackner C, Boerwinkle E, Leffert CC, Rahmig T, Hobbs HH. Molecular basis of apolipoprotein(a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J Clin Invest. 1991;87: 2077-2086.
27. Utermann G, Menzel HJ, Kraft HG, Duba HC, Kremmler HG, Seitz C. Lp(a) glycoprotein phenotypes: inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest. 1987;80:458-465.
28. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 1989;339:303-305.
29. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature. 1989;339:301-303.
30. Harpel PC, Gordon BR, Parker TS. Plasmin catalyses binding of lipoprotein(a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci U S A. 1989;86:3847-3851.
31. Rouy D, Grailhe P, Nigon F, Chapman J, Anglés-Cano E. Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. Arterioscler Thromb. 1991;11:629-638.
32. Boonmark NW, Xing JL, Zhuoying JY, Schwartz K, Zhang JL, Rubin EM. Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice. J Clin Invest. 1997;100:558-564.
33. Leebeek FWG, Knot EAR, Cate JWT, Traas DW. Severe thrombotic tendency associated with type I plasminogen deficiency. Am J Hematol. 1989;30:32-35.
34. Kozlowski KA, Berlet A, Robbins KC. Maywood II: a congenitally abnormal plasminogen with defective lysine-binding sites associated with stroke in a 16-year-old male. Fibrinolysis. 1995;9:17-27.
35. Hervio L, Chapman J, Thillet J, Loyau S, Anglés-Cano E. Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis? Blood. 1993;82:392-397.
36. Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem. 1966;15:45-52.
37. Khyse-Andersen J. Electroblotting of multiple gels: a single apparatus without buffer tank for rapid transfer of protein from polyacrylamide to nitrocellulose. J Biophys Biochem Methods. 1984;10:203-209.
38. Anglés-Cano E, Loyau S, Cardoso-Saldaña G, Couderc R, Gillery P. A novel kringle-4 number based recombinant apo(a) standard for human apo(a) phenotyping. J Lipid Res. 1999;40:354-359.
39. Fless GM, Snyder ML, Furbee JW, Garcia-Hedo MT, Mora R. Subunit composition of lipoprotein(a) protein. Biochemistry. 1994;33: 13492-13501.
40. Kazal LA, Amsel S, Miller OP, Tocantins LM. The preparation and some properties of fibrinogen precipitated from human plasma by glycine. Proc Soc Exp Biol Med. 1963;113:989-994.
41. Deutsch D, Mertz ET. Plasminogen purification from human plasma by affinity chromatography. Science. 1970;170:1095-1096.
42. Fleury V, Anglés-Cano E. Characterization of the binding of plasminogen to fibrin surfaces: the role of carboxy-terminal lysines. Biochemistry. 1991;30:7630-7638.
43. Grailhe P, Boyer-Neuman C, Haverkate F, Grimbergen J, Larrieu MJ, Anglés-Cano E. The mutation in fibrinogen Bicêtre II (γAsn308, Lys) does not affect the binding of t-PA and plasminogen to fibrin. Blood Coagul Fibrinolysis. 1993;4:679-687.
44. Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer. 1980;26:171-176.
45. Stocker JW, Heusser CH. Methods for binding cells to plastic: application to a solid-phase radioimmunoassay for cell-surface antigens. J Immunol Methods. 1979;26:87-95.
46. Kang C, Durlach V, Soulat T, Fournier C, Anglés-Cano E. Lipoprotein(a) isoforms display differences in affinity for plasminogen-like binding to human mononuclear cells. Arterioscler Thromb Vasc Biol. 1997;17:2036-2043.
47. Fraker PM, Speck JC. Protein and cell membrane iodinations with a sparingly soluble chloramide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril. Biochem Biophys Res Commun. 1978;80: 849-857.
48. Fleury V, Gurewich V, Anglés-Cano E. A study of the activation of fibrin-bound plasminogen by tissue-type plasminogen activator, single-chain urokinase and sequential combination of the activators. Fibrinolysis. 1993;7:887-896.
49. Gazzaruso C, Garzaniti A, Buscaglia P, Bonetti G, Falcone C, Fratino P, Finardi G, Geroldi D. Apolipoprotein(a) phenotypes and their predictive value for coronary heart disease: identification of an operative cut-off of apolipoprotein(a) polymorphism. J Cardiovasc Risk. 1998;5:37-42.
50. Hervio L, Durlach V, Girard-Globa A, Anglés-Cano E. Multiple binding with identical linkage: a mechanism that explains the effect of lipoprotein(a) on fibrinolysis. Biochemistry. 1995;34:13353-13358.
51. Sagripanti A, Barsotti G. Hypercoagulability, intraglomerular coagulation, and thromboembolism in nephrotic syndrome. Nephron. 1995; 70:271-281.
52. Thabet MA, Salcedo JR, Chan JCM. Hyperlipidemia in childhood nephrotic syndrome. Pediatr Nephrol. 1993;7:559-566.
53. Islam S, Gutin B, Smith C, Treiber F, Kamboh MI. Association of apolipoprotein(a) phenotypes in children with family history of premature coronary artery disease. Arterioscler Thromb. 1994;14: 1609-1616.
54. Taimela S, Viikari JSA, Porkka KVK, Dahlen GH. Lipoprotein(a) levels in children and young adults: the influence of physical activity: the cardiovascular risk in young Finns study. Acta Paediatr. 1994;83: 1258-1263.
55. Bailleul S, Couderc R, Rossignol C, Fermanian J, Boutouchent F, Farnier MA, Etienne J. Lipoprotein(a) in childhood: relation with other atherosclerosis risk factors and family history of atherosclerosis. Clin Chem. 1995;41:241-245.
56. Gomez Gerique JA, Porres A, Lopez Martinez D, Alvarez Sala LA, Blazquez E, Montoya MT, de Oya M. Levels of lipoprotein(a) and plasma lipids in Spanish children aged from 4 to 18 years. Acta Paediatr. 1996;85:38-42.
57. Hughes SD, Lou XJ, Ighani S, Verstuyft J, Grainger DJ, Lawn RM, Rubin EM. Lipoprotein(a) vascular accumulation in mice. In vivo analysis of the role of lysine binding sites using recombinant adenovirus. J Clin Invest. 1997;100:1493-1500.
58. Tavola A, D'Angelo SV, Bandello F, Brancato R, Parlavecchia M, Safa O, D'Angelo A. Central retinal vein and branch artery occlusion associated with inherited plasminogen deficiency and high lipoprotein(a) levels: a case report. Thromb Res. 1995;80:327-331.
59. Xiao Q, Danton MJ, Witte DP, Kowala MC, Valentine MT, Bugge TH, Degen JL. Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis. Proc Natl Acad Sci U S A. 1997;94:10335-10340.
60. Kario K, Matsuo T, Kobayashi H, Matsuo M, Asada R, Koide M. High lipoprotein(a) levels in chronic hemodialysis patients are closely related to the acute phase reaction. Thromb Haemost. 1995;74: 1020-1024.
61. Webb AT, Reaveley DA, OíDonnel M, OíConnor B, Seed M, Brown EA. Does cyclosporin increase lipoprotein(a) concentrations in renal transplant recipients? Lancet. 1993;341:268-270.
62. Farmer JA, Ballantyne CM, Frazier OH. Lipoprotein(a) and apolipoprotein changes after cardiac transplantation. J Am Coll Cardiol. 1991;18:926-930.
63. Senti M, Puig JM, Lloveras J, Aubó C, Mir M, Barbosa F, Oliveras A, Masramón J. Effect of cyclosporine on serum lipoprotein(a) levels in renal transplant recipients. Transplant Proc. 1997;29:2404-2405.
64. Zilleruelo G, Hsia SL, Freundlich M, Gorman HM, Strauss J. Persistence of serum lipid abnormalities in children with idiopathic nephrotic syndrome. J Pediatr. 1984;104:61-64.